INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (NCT04455841)

🧪 Interventions in This Study

• INCB000928 (DRUG)
• ruxolitinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (34 Sites)

Showing the first 25 of 34 sites.

• City of Hope National Medical Center — Duarte, California
• City of Hope Orange County — Irvine, California
• Usc Norris Comprehensive Cancer Center — Los Angeles, California
• Stanford Cancer Center — Palo Alto, California
• Prebys Cancer Center — San Diego, California
• Emory University - Winship Cancer Institute — Atlanta, Georgia
• Emory University-Winship Cancer Institute — Atlanta, Georgia
• Start Midwest — Grand Rapids, Michigan
• Washington University School of Medicine — St Louis, Missouri
• Weill Cornell Medical Centers — New York, New York
• Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy — Durham, North Carolina
• Vanderbilt University Medical Center — Nashville, Tennessee
• Md Anderson Cancer Center — Houston, Texas
• Princess Margaret Cancer Center — Toronto, Ontario
• McGill University Jewish General Hospital — Montreal, Quebec
• Centre Hospitalier D'Angers — Angers,
• Institut Paoli Calmettes — Marseille,
• Hospital Saint Louis — Paris,
• Azienda Ospedaliera Papa Giovanni Xxiii — Bergamo,
• S Orsolas University Hospital Seragnoli Institute of Hematology — Bologna,
• Azienda Ospedaliero-Universitaria Careggi (Aouc) — Florence,
• Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano — Orbassano,
• Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo — Pavia,
• Ospedale Santa Maria Della Misericordia Perugia — Perugia,
• Tokyo Medical and Dental University Hospital — Bunkyō City,

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Anemia

• The Immediate and Long-term Effects of a Novel Marine-based Iron Supplement in Adult Females — Huntsville, Alabama
• Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia — Boston, Massachusetts
• INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections — Phoenix, Arizona
• Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia — Birmingham, Alabama
• Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Birmingham, Alabama

Explore by condition: All Anemia clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.